Skip NavigationSkip to Content
Return Return to Search Results

CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover

  1. Author:
    Orr, S. J.
    Morgan, N. M.
    Elliott, J.
    Burrows, J. F.
    Scott, C. J.
    McVicar, D. W.
    Johnston, J. A.

  2. Author Address

    Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland. Queens Univ Belfast, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland. NCI, Frederick Canc Res & Dev Ctr, Expt Immunol Lab, Div Basic Sci, Frederick, MD USA.;Johnston, JA, Queens Univ Belfast, Ctr Canc Res & Cell Biol, 2nd Floor,Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.;jim.johnston@qub.ac.uk
    1. Year: 2007
    2. Date: Feb
  2. Journal: Blood
    1. 109
    2. 3
    3. Pages: 1061-1068
  4. Type of Article: Article
  5. ISSN: 0006-4971
  1. Abstract:

    CD33 is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family of inhibitory receptors and a therapeutic target for acute myeloid leukemia (AML). CD33 contains a cytoplasmic Immunoreceptor tyrosine-based inhibitory motif (ITIM), which can recruit SHP-1 and SHP-2. How CD33 expression is regulated is unclear. Suppressor of cytokine signaling 3 (SOCS3) is expressed in response to cytokines, LIPS, and other PAMPs, and competes with SHP-1/2 binding to ITIMs of cytokine receptors, thereby inhibiting signaling. In this study, using peptide pull-down experiments, we found that SOCS3 can specifically bind to the phosphorylated ITIM of CD33. Additionally, following cross-linking SOCS3 can recruit the ECS E3 ligase resulting in accelerated proteasomal degradation of both CD33 and SOCS3. Our data suggest that the tyrosine motifs in CD33 are not important for internalization, while they are required for degradation. Moreover, SOCS3 inhibited the CD33-induced block on cytokine-induced proliferation. This is the first receptor shown to be degraded by SOCS3 and where SOCS3 and its target protein are degraded concomitantly. Our findings clearly suggest that during an inflammatory response, the inhibitory receptor CD33 is lost by this mechanism. Moreover, this has important clinical implications as tumors expressing SOCS3 may be refractory to alpha-CD33 therapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1182/blood-2006-05-023556
  3. View record in Web of Science®
  4. WOS: 000244132800038

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel